New Managing Director of UK & Ireland for Novartis

pharmafile | February 17, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis 

Novartis announced the appointment of Haseeb Ahmad as Managing Director for UK & Ireland. He joins from MSD, known as Merck in North America, where he performed the role of Managing Director for Greece, Cyprus and Malta.

Ahmad brings with him 20 years of experience working within the pharmaceutical industry; with 13 years based in the UK, the transition to working within as Managing Director of the region should not require a drastic learning curve in knowledge on the region. Ahmad began his career with MSD as a sales representative before moving into managerial positions at Ivax Pharmaceuticals and Schering-Plough. Ten years after his first position at MSD, he returned to work as Strategy and Operations Director before making the step up to Managing Director.

“I am immensely proud to join the Novartis UK team. As a market, the UK is very important. It is at the forefront of healthcare reform and through partnership with the NHS, Novartis can deliver important medicines and innovative solutions for patients,” commented Ahmad upon his appointment. “As a company, I have greatly admired Novartis and am thrilled to accept this role. Novartis has a rich history and heritage, life changing medicines and an exciting pipeline. But most importantly, Novartis lives by its strong values to do business and deliver for patients in the right way.”

Marie-France Tschudin, Head Novartis Pharmaceuticals, Region Europe, adds: “I am delighted that Haseeb has joined Novartis to lead our UK Pharmaceuticals business as Managing Director and as Country President for the UK. I look forward to working with Haseeb and to the continued success of the UK & Ireland teams.”

Related Content

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content